comparemela.com

Page 5 - Mcepi News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Bharat Biotech To Get $19 Million For Development Of Variant Proof Covid Vaccine

CEPI on Tuesday said it will provide up to USD 19.3 million (about Rs 149 crore) to Bharat Biotech International, the University of Sydney, and Switzerland-based ExcellGene SA for the development of a "variant-proof" SARS-CoV-2 vaccine candidate.

Covid-19 and capitalism

Despite many predictions over the years by the World Health Organisation that a new pandemic was fairly certain, fairly soon, capitalist governments and businesses failed to do the research and development in advance that could have provided us with medical capacity to limit its effect, or environmental measures which might even have prevented the outbreak.

CEPI Partners with Japan s NEC Group to Develop Artificial Intelligence-designed Broadly Protective Betacoronavirus Vaccine

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.